Zentalis Pharmaceuticals (ZNTL) to Release Earnings on Tuesday

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) is expected to release its earnings data before the market opens on Tuesday, February 25th. Analysts expect Zentalis Pharmaceuticals to post earnings of ($0.74) per share for the quarter.

Zentalis Pharmaceuticals Price Performance

ZNTL stock traded down $0.15 during trading on Friday, hitting $2.32. 1,019,827 shares of the company traded hands, compared to its average volume of 2,438,988. The stock's 50-day simple moving average is $2.55 and its 200 day simple moving average is $3.08. The company has a market cap of $165.33 million, a PE ratio of -0.93 and a beta of 1.81. Zentalis Pharmaceuticals has a 1 year low of $1.61 and a 1 year high of $18.07.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on ZNTL. HC Wainwright reduced their price target on Zentalis Pharmaceuticals from $20.00 to $10.00 and set a "buy" rating for the company in a research report on Wednesday, January 29th. UBS Group reduced their price target on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a "neutral" rating for the company in a research report on Tuesday, January 28th. Wedbush reiterated a "neutral" rating and set a $4.00 price target on shares of Zentalis Pharmaceuticals in a research report on Friday, January 24th. Guggenheim reduced their price target on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a "buy" rating for the company in a research report on Friday, November 15th. Finally, Wells Fargo & Company reduced their price target on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating for the company in a research report on Thursday, January 30th. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $8.24.

Insider Buying and Selling at Zentalis Pharmaceuticals

In other news, insider Ingmar Bruns purchased 20,000 shares of the stock in a transaction dated Thursday, February 6th. The shares were purchased at an average cost of $2.28 per share, with a total value of $45,600.00. Following the completion of the purchase, the insider now directly owns 36,629 shares of the company's stock, valued at approximately $83,514.12. The trade was a 120.27 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Jan Skvarka purchased 60,000 shares of the stock in a transaction dated Friday, January 31st. The stock was purchased at an average cost of $1.72 per share, for a total transaction of $103,200.00. Following the completion of the purchase, the director now directly owns 149,551 shares of the company's stock, valued at approximately $257,227.72. The trade was a 67.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 3.60% of the stock is owned by corporate insiders.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.